We are live on ! Find out more
EFTR

eFFECTOR Therapeutics, Inc. Common Stock
EFTR

Delisted

EFTR was delisted on the 2nd of July, 2024.

Back to rankings

3 hedge funds and large institutions have $4.33K invested in eFFECTOR Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% less funds holding

Funds holding: 18 → 3 (-15)

98% less capital invested

Capital invested by funds: $251K → $4.33K (-$247K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 15

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
-15
Holders Change %
-83.33%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$64.9K
2
CG
Carlyle Group
District of Columbia
-$55.9K
3
PA
Parallel Advisors
California
-$19.7K
4
UBS Group
UBS Group
Switzerland
-$17.9K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$7.42K

EFTR Hedge Fund Activity: Q3 2024 in Review

3 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q3 2024, worth a combined $4.33K — down 98% from $251K a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of EFTR and 0 opened new positions — a net loss of 15 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Sabby Management, cutting an estimated $64.9K.

  • 3 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q3 2024, down from 18 in Q2 2024.
  • Funds reported $4.33K of eFFECTOR Therapeutics, Inc. Common Stock stock for Q3 2024, down 98% quarter-over-quarter.
  • 0 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q3 2024 and 15 closed out, a net change of -15 holders.
  • The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q3 2024 was Sabby Management, an estimated $64.9K sold.

Based on aggregated 13F filings for Q3 2024.